



May 19, 2026

Company name: SanBio Co., Ltd.  
(Code: 4592 TSE Growth)  
Name of representative: Keita Mori, Representative Director and President  
For inquiries, contact: Yoshihiro Kakutani, Corporate Officer of Management Administration  
(Phone: 03-6264-3481)

## **Notice Concerning Chuikyo Approval of Proposed NHI Price for AKUUGO<sup>®</sup> and Revision of Consolidated Earnings Forecast for FY Ending Jan. 2027**

SanBio Co., Ltd. (hereinafter, the “Company”) hereby announces that today the Central Social Insurance Medical Council (the “Chuikyo”) approved the proposed National Health Insurance (NHI) price for “AKUUGO<sup>®</sup> Suspension for Intracranial Implantation” (INN: vandefitemcel; “AKUUGO<sup>®</sup>”). In connection with this development, the Company has revised its consolidated earnings forecast for the fiscal year ending January 31, 2027 as below. Please note that the final NHI price and reimbursement status will be officially determined upon publication in the Official Gazette by the Ministry of Health, Labour and Welfare.

### **1. Proposed NHI price for AKUUGO<sup>®</sup>**

The product overview of AKUUGO<sup>®</sup> and the proposed NHI price approved by the Chuikyo are as follows.

- Brand name: AKUUGO<sup>®</sup> Suspension for Intracranial Implantation
- INN: vandefitemcel
- Indication: Improvement of chronic motor paralysis associated with traumatic brain injury
- Proposed NHI price: 72,716,528 yen (tax included)

The proposed NHI price for AKUUGO<sup>®</sup> approved by the Chuikyo was calculated in accordance with the cost-accounting method applicable to regenerative medicine products. The final NHI price and reimbursement listing are expected to be officially determined through publication in the Official Gazette by the Ministry of Health, Labour and Welfare on May 20.

Following NHI listing, the Company plans to initially launch AKUUGO<sup>®</sup> primarily at medical institutions that participated in clinical trials of the product, while carefully establishing a medical collaboration framework encompassing patient treatment from administration through rehabilitation, and proceeding with a phased market introduction. Initial shipments are expected to commence in the second half of the fiscal year (August 2026 to January 2027), following completion of product adoption procedures at each hospital. In addition, the Company intends to steadily and safely conduct the required post-marketing clinical trials and post-marketing surveillance during the seven-year conditional and time-limited marketing authorization period, with the aim of obtaining full approval. Further, the Company positions AKUUGO<sup>®</sup>'s current indication for traumatic brain injury as a platform for future global expansion, including into the U.S., as well as for potential expansion into additional indications such as ischemic stroke, with the goal of enhancing medium-to long-term corporate value.

### **2. Revision to the consolidated earnings forecast for the fiscal year ending January 31, 2027**

The Company revised its consolidated earnings forecast for the fiscal year ending January 31, 2027 (February 1, 2026–January 31, 2027), which was originally announced on March 17, 2026, as shown in the table below.

The operating revenue forecast is based on the assumption that the proposed NHI price for AKUUGO<sup>®</sup>,

approved today by the Chuikyo, will be officially adopted, as well as on the Company's plan to proceed with a careful rollout centered on medical institutions that participated in clinical trials of the product. Because a substantial portion of the cost of revenue has already been recognized as R&D expense in prior periods, cost of revenue to be recorded in the current fiscal year is expected to be minimal. Accordingly, the operating income forecast primarily reflects the anticipated increase in operating revenue. The ordinary income forecast reflects foreign exchange gains recognized as of today on foreign currency-denominated loans extended to the Company's consolidated subsidiaries and related receivables. Likewise, the net income attributable to owners of parent forecast reflects the actual amount of income tax deferred recognized in connection with deferred tax liabilities associated with foreign currency-denominated loans to the Company's consolidated subsidiaries and related receivables.

Revision to the consolidated earnings forecast for the fiscal year ending January 31, 2027 (February 1, 2026–January 31, 2027)

	Operating revenue	Operating income	Ordinary income	Net income attributable to owners of parent	Net income per share
Previous forecast (A) (Announced March 17, 2026)	Million yen —	Million yen (5,625)	Million yen (5,632)	Million yen (5,635)	Yen (72.21)
Revised forecast (B)	396	(5,229)	(5,074)	(5,133)	(65.77)
Change (B) – (A)	396	396	558	502	
% change	—	—	—	—	
(Ref.) Results for the fiscal year ended January 31, 2026	—	(3,794)	(4,291)	(3,842)	(52.55)

Notes:

1. The above forecasts have been prepared based on information available as of the date of this release. Actual results may differ from the forecast figures due to various factors that may arise in the future.
2. No revision has been made to the consolidated earnings forecast for the first half of the fiscal year ending January 31, 2027.

<Reference information>

Consolidated earnings forecast for the first half of the fiscal year ending January 31, 2027 (February 1, 2026–July 31, 2026)

	Operating revenue	Operating income	Ordinary income	Net income attributable to owners of parent	Net income per share
Previous forecast (A) (Announced March 17, 2026)	Million yen —	Million yen (2,906)	Million yen (2,908)	Million yen (2,909)	Yen (37.28)
(Ref.) Results for the first half of the fiscal year ended January 31, 2026	—	(1,888)	(2,481)	(1,997)	(27.80)

End